A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2018 Nov 13

PMID 30416896

Citations 1

Authors

Vivian C Agumadu

Kamleshun Ramphul

Stephanie G Mejias

Ruhi Sonaye

Shaheen Sombans

Petras Lohana

Affiliations

Soon will be listed here.

Abstract

Asthma is a chronic respiratory condition that is characterized by reversible airflow obstruction. Interleukin-5 (IL-5) is involved in the pathophysiology of the disease and drugs targeting IL-5 have been studied for years as a possible treatment option for severe asthma. In this review, the authors searched PubMed for major drug therapies and clinical trials against IL-5. A total of 29 articles met the criteria for selection and were shortlisted; of these, 10 papers were on benralizumab, 14 on mepolizumab, and five on reslizumab. The three drugs proved to be safe and efficacious for patients with severe asthma, leading to decreased rates of asthma exacerbations, lowered levels of eosinophils, and improved pulmonary functions in various studies. Patients also reported an improvement in the quality of life. The side effects of these three drugs were mild and no deaths directly linked to the drug were reported. However, longer duration studies are required to draw firm and strong conclusions on the safety of these therapeutic agents.

Citing Articles

The epithelial barrier theory: Development and exacerbation of allergic and other chronic inflammatory diseases.

Kucuksezer U, Ozdemir C, Yazici D, Pat Y, Mitamura Y, Li M Asia Pac Allergy. 2023; 13(1):28-39.

PMID: 37389096 PMC: 10166244. DOI: 10.5415/apallergy.0000000000000005.

References

Ortega H, Liu M, Pavord I, Brusselle G, FitzGerald J, Chetta A . Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371(13):1198-207. DOI: 10.1056/NEJMoa1403290. View

Tsukamoto N, Takahashi N, Itoh H, Pouliquen I . Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. Clin Pharmacol Drug Dev. 2016; 5(2):102-8. PMC: 5042051. DOI: 10.1002/cpdd.205. View

Menzies-Gow A, Kay A, Robinson D . Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2002; 167(2):199-204. DOI: 10.1164/rccm.200208-789OC. View

Shi H, Xiao C, Zhong D, Qin S, Liu Y, Liang G . Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med. 1998; 157(1):204-9. DOI: 10.1164/ajrccm.157.1.9703027. View

Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig M . Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003; 112(7):1029-36. PMC: 198522. DOI: 10.1172/JCI17974. View

Accordini S, Corsico A, Cerveri I, Gislason D, Gulsvik A, Janson C . The socio-economic burden of asthma is substantial in Europe. Allergy. 2007; 63(1):116-24. DOI: 10.1111/j.1398-9995.2007.01523.x. View

Laviolette M, Gossage D, Gauvreau G, Leigh R, Olivenstein R, Katial R . Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013; 132(5):1086-1096.e5. PMC: 4172321. DOI: 10.1016/j.jaci.2013.05.020. View

Korn S, Both J, Jung M, Hubner M, Taube C, Buhl R . Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol. 2011; 107(6):474-9. DOI: 10.1016/j.anai.2011.09.001. View

Yamada T, Sun Q, Zeibecoglou K, Bungre J, North J, Kay A . IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells. J Allergy Clin Immunol. 1998; 101(5):677-82. DOI: 10.1016/S0091-6749(98)70177-0. View

10.

Walsh G . Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci. 1999; 36(5):453-96. DOI: 10.1080/10408369991239277. View

11.

Lamkhioued B, Gounni Abdelilah S, Hamid Q, Mansour N, Delespesse G, Renzi P . The CCR3 receptor is involved in eosinophil differentiation and is up-regulated by Th2 cytokines in CD34+ progenitor cells. J Immunol. 2002; 170(1):537-47. DOI: 10.4049/jimmunol.170.1.537. View

12.

Murphy K, Jacobs J, Bjermer L, Fahrenholz J, Shalit Y, Garin M . Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2017; 5(6):1572-1581.e3. DOI: 10.1016/j.jaip.2017.08.024. View

13.

Pouliquen I, Kornmann O, Barton S, Price J, Ortega H . Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015; 53(12):1015-27. PMC: 4647865. DOI: 10.5414/CP202446. View

14.

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View

15.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

16.

Castro M, Wenzel S, Bleecker E, Pizzichini E, Kuna P, Busse W . Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014; 2(11):879-890. DOI: 10.1016/S2213-2600(14)70201-2. View

17.

Takatsu K . Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011; 87(8):463-85. PMC: 3313690. DOI: 10.2183/pjab.87.463. View

18.

Rosenberg H, Phipps S, Foster P . Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007; 119(6):1303-10. DOI: 10.1016/j.jaci.2007.03.048. View

19.

Ortega H, Yancey S, Mayer B, Gunsoy N, Keene O, Bleecker E . Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 4(7):549-556. DOI: 10.1016/S2213-2600(16)30031-5. View

20.

OByrne P . The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med. 2007; 176(11):1059-60. DOI: 10.1164/rccm.200708-1264ED. View